NeuroSense Therapeutics

NeuroSense Therapeutics is a Herzliya, Israel-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its lead program is PrimeC, an extended-release fixed-dose oral combination of ciprofloxacin and celecoxib in Phase 2b/3 for amyotrophic lateral sclerosis, with a completed Phase 2 evaluation in Alzheimer's disease and preclinical work in Parkinson's; earlier-stage programs include StabiliC (Parkinson's) and CogniC (Alzheimer's). On September 3, 2026 the company unveiled an accelerated, capital-efficient development strategy to advance PrimeC toward potential approval in ALS, and H.C. Wainwright initiated coverage with a Buy rating.